Link Pharma Chem turns profitable with ₹7.69 cr net profit in FY26
Link Pharma Chem Limited returned to profitability in FY26, reporting a net profit of ₹7.69 crore compared to a net loss of ₹102.73 crore in the previous year. Revenue from operations increased to ₹2,743.15 crore from ₹2,543.34 crore in FY25. The Board re-appointed Mr. Rishikesh Thakur as Managing Director for a period of three years effective from September 24, 2026, subject to shareholder approval.
*this image is generated using AI for illustrative purposes only.
Link Pharma Chem Limited has reported its audited financial results for the quarter and financial year ended March 31, 2026. The company returned to profitability for the full fiscal year, recording a net profit of ₹7.69 crore compared to a net loss of ₹102.73 crore in the previous year. Revenue from operations for the year ended March 31, 2026, stood at ₹2,743.15 crore, up from ₹2,543.34 crore in the corresponding period of the previous year. Total income for the year rose to ₹2,763.49 crore from ₹2,561.99 crore in FY25.
Board Re-appoints Managing Director
The Board of Directors of Link Pharma Chem Limited at its meeting held on May 21, 2026, re-appointed Mr. Rishikesh Thakur as the Managing Director of the company for a further period of three years with effect from September 24, 2026. This appointment is subject to the approval of shareholders at the ensuing Annual General Meeting. Mr. Rishikesh Thakur holds a B. Eng. in Polymer from London Metropolitan University and possesses over 15 years of experience in the chemical business, including manufacturing, R&D, and project development. He is the son of Mr. Satish G. Thakur, the Chairman & Whole-time Director of the company.
Financial Performance for FY26
The company's total expenses for the year increased marginally to ₹2,749.98 crore from ₹2,702.24 crore in the previous year. Profit before tax for the year was recorded at ₹13.51 crore, a significant improvement from the loss before tax of ₹140.25 crore in FY25. The finance costs for the year reduced to ₹52.98 crore from ₹77.55 crore in the prior year.
Quarterly Results
For the quarter ended March 31, 2026, the company reported a net loss of ₹40.86 lakh, compared to a net loss of ₹35.02 lakh in the corresponding quarter of the previous year. Revenue from operations for the quarter stood at ₹658.88 crore, slightly higher than the ₹644.66 crore reported in the same period last year. Total expenses for the quarter increased to ₹722.62 crore from ₹704.72 crore in Q4 FY25.
Key Financial Metrics
The following table summarizes the audited financial results for Link Pharma Chem Limited for the year and quarter ended March 31, 2026:
| Particulars | Year Ended Mar 31, 2026 (₹ in Lakhs) | Year Ended Mar 31, 2025 (₹ in Lakhs) | Quarter Ended Mar 31, 2026 (₹ in Lakhs) | Quarter Ended Mar 31, 2025 (₹ in Lakhs) |
|---|---|---|---|---|
| Revenue from operations | 2,743.15 | 2,543.34 | 658.88 | 644.66 |
| Total Income | 2,763.49 | 2,561.99 | 673.62 | 656.45 |
| Total Expenses | 2,749.98 | 2,702.24 | 722.62 | 704.72 |
| Profit/(Loss) before tax | 13.51 | (140.25) | (49.00) | (48.27) |
| Net Profit/(Loss) for the period | 7.69 | (102.73) | (40.86) | (35.02) |
Assets and Liabilities
As of March 31, 2026, the company's total assets stood at ₹2,496.22 crore, compared to ₹2,329.32 crore in the previous year. Total equity increased to ₹1,278.92 crore from ₹1,266.21 crore. Cash and cash equivalents improved significantly to ₹54.59 crore as of March 31, 2026, from ₹6.45 crore in the prior year. The company's operations fall under a single segment, namely the manufacture and sale of chemicals.
Historical Stock Returns for Link Pharma Chem
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.88% | +1.27% | -3.45% | -17.60% | -20.61% | -16.91% |
Will Link Pharma Chem sustain full-year profitability in FY27 given the recurring quarterly losses in Q4 FY26, and what operational changes are planned to address this seasonal weakness?
How might Mr. Rishikesh Thakur's re-appointment as Managing Director influence the company's strategic direction, particularly in R&D investment and new product development over the next three years?
With finance costs already reduced significantly, what further debt restructuring or refinancing strategies is Link Pharma Chem likely to pursue to improve net margins going forward?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
